SEPTInvestingStart Free

BOLT 10-Q: SEC filing

Bolt Biotherapeutics

Filed with the SEC on · accession 0001193125-26-458877

BOLT filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Bolt Biotherapeutics filed its Q3 2026 10-Q, which includes a restatement adjustment to previously reported interim financials and disclosure of a subsequent event involving a securities purchase agreement for Series D non-voting convertible preferred stock.

For details, click here →How to read a 10-Q →

Key details

FilerBolt Biotherapeutics, Inc.
Counterparty/agreementPrana Therapies Inc.
Agreement counterpartyGenmab
Development agreement counterpartyToray

✦ Ask GOAX AI about this filing — what it means for BOLT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BOLT?

Click here

Frequently asked questions

What did BOLT file with the SEC on Nov 13, 2026?

BOLT filed a 10-Q (SEC filing). Bolt Biotherapeutics filed its Q3 2026 10-Q, which includes a restatement adjustment to previously reported interim financials and disclosure of a subsequent event involving a securities purchase agreement for Series D non-voting convertible preferred stock.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other BOLT SEC filings

Get alerts when BOLT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BOLT overviewBOLT analysisBOLT newsLatest SEC filings